Facts {#Sec1}
=====

Abnormal transcriptional activity is an important part of tumorigenesis.The activity of transcription factors is regulated by post-translational modifications, especially lysine methylation.Several protein lysine methyltransferase inhibitors have been proven as promising new targets for anticancer therapy.

Open questions {#Sec2}
==============

Lysine methylation of transcription factors has been discovered in recent years. What role does this post-translational modification play in cancer?What is the specific mechanism of lysine methylation in regulating transcription factor activity?Epigenetics provides promising new targets for anticancer therapy. Does targeting lysine methylation of transcription factors provide important clinical value?

Introduction {#Sec3}
============

Transcription factors are a group of proteins that can bind to specific sequences upstream of the 5′ terminus of target genes, typically considered the promoter region^[@CR1],[@CR2]^. In this way these transcription factors can inhibit or enhance gene expression and ensure specific temporal target gene expression^[@CR3]^. Under normal circumstances, promoter-specific transcription factors contribute in basic biological activities including differentiation^[@CR4]^, development^[@CR5]^, and metabolism^[@CR6]^. Importantly, dysregulation of these transcriptional programs can lead to malignant growth and cancer formation^[@CR7],[@CR8]^. Transcription factors can be subject to a variety of enzyme-catalyzed post-translational modifications (PTMs) in response to environmental changes, especially in disease occurrence and tumorigenesis^[@CR9],[@CR10]^.

These transcription factor PTMs are added and removed by the same enzyme families that are involved in histone modifications like acetylation, phosphorylation, and methylation^[@CR11]--[@CR13]^. Specific modifications have selective effects on transcription factor functions, resulting in specific gene expression alterations. It has been demonstrated in the literature that transcription factor phosphorylation and acetylation can promote carcinogenesis by regulating transcriptional activity^[@CR14],[@CR15]^. We have greatly improved our understanding of transcription factor methylation with the development of mass-spectrometric techniques in the last few decades^[@CR16]^.

Protein methylation occurs at specific sites on substrates, with lysine methylation being one of the important forms^[@CR17]--[@CR19]^. The lysine (K) ε-amino group of protein substrates can accept up to three methyl groups, resulting in either mono-, di-, or trimethyl lysine, in a process termed lysine methylation^[@CR20]--[@CR22]^. Recent studies have revealed that a number of transcription factors have been found to be modified by lysine methyltransferases (KMTs)^[@CR23]--[@CR25]^, resulting in specific gene expression alterations^[@CR26],[@CR27]^. The abnormal expression of methyltransferases in many tumor types, which has been proven to be associated with tumorigenesis and cancer development, has become the focus of anticancer research^[@CR28]--[@CR30]^. In addition to histone methylation^[@CR31]^, transcription factor methylation modification is also an important aspect for the development of cancer^[@CR27],[@CR32]^.

To date, multiple studies have demonstrated that lysine methylation of transcription factors can directly regulate target gene expression by altering transcription factor stability and function. In this review, we summarize recent studies on lysine methylation of transcription factors, aiming to underline the biological significance and highlight the potential clinical value of lysine methylation of transcription factors in cancer.

The process of protein lysine methylation {#Sec4}
=========================================

The process of protein lysine methylation consists of enzymes adding or removing methyl groups on particular substrates^[@CR33],[@CR34]^ (Fig. [1](#Fig1){ref-type="fig"}). The lysine ε-amino group of proteins can accept up to three methyl groups, resulting in either mono-, di-, or trimethyl lysine, (me1, me2, or me3) with the various methylation states of lysines exerting distinct functions^[@CR35]^. To date, more than 50 KMTs and 20 lysine demethylases (KDMs) have been reported^[@CR36]^.Fig. 1The process of lysine methylation and demethylation.Lysine (K) methylation is a dynamic and reversible post-translational modification (PTM) of proteins. Generally, the lysine ε-amino groups can accept up to three methyl groups, resulting in mono-, di-, or trimethyllysine. Lysine methyltransferases (KMTs) catalyze the addition of methyl groups to substrates, while lysine demethylases (KDMs) remove methyl groups. K, lysine; PTM, post-translational modification; KMTs, lysine methyltransferases; KDMs, Lysine methyltransferases

Lysine methyltransferases {#Sec5}
=========================

The lysine methyltransferases that methylate histones can also methylate non-histone proteins^[@CR36]^, which have been categorized into eight classes according to their sequences and structures. The two largest classes are the SET proteins, containing a defined SET-domain, and the seven-β-strand (7BS) proteins, which have a typical core fold of seven strands^[@CR25]^. The SET-domain proteins mostly target the lysines in the flexible tails of histones. In general, the lysine ε-amino group can accept up to three methyl groups, resulting in either mono-, di-, or trimethyl lysine, with the different methylation states of lysine exerting distinct functions^[@CR35]^. In contrast, the majority of 7BS KMTs target a single protein or a group of highly related proteins. Complete understanding of the functional consequences of methylation of 7BS KMT targets still remains elusive, and in most cases the relationship between biological functionality and the biochemistry is challenging to understand^[@CR37]^.

Lysine demethylases {#Sec6}
===================

Lysine methylation had historically been considered irreversible until the first histone demethylase, Lys-specific demethylase 1 (LSD1, also known as KDM1A, BHC110, and AOF2), was discovered in 2004^[@CR38],[@CR39]^. LSD2 (also known as KDM1B) is the only homolog of LSD1 in the human genome. LSD1 and LSD2 both belong to the first KDM family of flavin-dependent monoamine oxidases, and only demethylate monomethyl and dimethyl lysine residues^[@CR40]^. The second family of KDMs consist of Jumonji C (JMJC) domain-containing proteins^[@CR41]^, which use an oxygenase mechanism to demethylate monomethylated, dimethylated, and trimethylated lysine residues^[@CR18]^.

Substrates {#Sec7}
==========

Since the discovery of protein methylation more than 50 years ago^[@CR42]^, most studies have focused on histone methylation in epigenetic domains^[@CR43]^. However, with the development of mass-spectrometric techniques, there has been extensive broadening of our understanding of known PTMs and the corresponding protein targets^[@CR16],[@CR44],[@CR45]^. Recent developments in protein mass spectrometry have allowed for high-throughput identification of lysine-methylated proteins, and nearly 2000 methyl modifications on lysine residues, distributed roughly between 1200 different proteins, have been reported in the human proteome. However, the biological function of the majority of these methylations still awaits identification^[@CR37]^.

Many of the dynamic changes in gene expression that occur in response to extracellular signals are mediated by PTMs that regulate the activity of promoter-specific transcription factors^[@CR46],[@CR47]^. Lysine methylation is emerging as an important regulatory mechanism of transcription factor function, where alteration of this modification activates or represses gene expression. The biomedical significance of non-histone lysine methylation, including of transcription factors, in several human diseases has been explored in recent years^[@CR48],[@CR49]^.

Regulatory mechanisms of lysine methylation {#Sec8}
===========================================

Many review articles have focused on the various effects of transcription factor phosphorylation^[@CR15],[@CR50]^, SUMOylation^[@CR51]^, ubiquitination^[@CR52]^, acetylation^[@CR14]^, and glycosylation^[@CR10]^. Like other PTMs, protein lysine methylation can directly regulate distinct aspects of transcription factor function, including protein stability, cellular localization, DNA-binding affinity, protein--protein interactions, and crosstalk with other PTMs. Although some lysine methylation phenomena are observed in some cases, the specific regulatory mechanisms still remain to be clarified^[@CR53]--[@CR56]^. Herein we discuss the five major regulatory mechanisms of lysine methylation based on the current literature (Fig. [2](#Fig2){ref-type="fig"} and Table [1](#Tab1){ref-type="table"}).Fig. 2The regulation mechanisms of lysine methylation of transcription factors and the downstream effects on cell biology.Lysine methylatioin can regulate transcription factor (TF) function by altering protein stability, subcellular localization, DNA-binding affinity, protein--protein interactions, and crosstalk with other PTMs. Notably, lysine methylation modifications may alter cellular biological processes positively (in green) or negatively (in red). **a** Protein stability can be regulated by lysine methylation indirectly. **b** Like phosphorylation, lysine methylation can also alter nuclear localization of transcription factors, thus regulating transcriptional activity. **c** Lysine methylation positively or negatively regulates promoter binding affinity of transcription factors, thereby altering transcription of target genes. **d** Lysine methylation can affect protein--protein interactions. Methylated lysine can be recognized by proteins that contain special motifs such as chromo, tudor, or malignant brain tumor domains, resulting in differential biological effects. **e** Lysine methylation regulates other PTMs in the same or adjacent sites. TF, transcription factor; me, methyl group; ac, acetyl group; P, phosphate group; Ub, ubiquitin; DCAF1, DDB1-CUL4-associated factor 1; MBD, methylation-binding domain; p300, lysine acetyltransferase p300; GLP, histone methyltransferase GLP; \*the methylation status is unknownTable 1The main regulatory mechanisms of transcription factor lysine methylationMechanismSubstrate^a^Enzyme^b^Tumor typeTranscription activityReferencesProtein stabilityRORαK38me1EZH2Breast cancerInhibition^[@CR60]^RelAK314me1\
K315me1SET7MEFs (mouse cardio myocytes),\
U2OS(osteosarcoma cell), A549(NSCLC cell)Inhibition^[@CR62]^Nuclear localizationP53K372me1SET7293F, U2OS(osteosarcoma cell), H1299(NSCLC cell)Activation^[@CR64]^ERαK302me1SET7Breast cancerActivation^[@CR65]^DNA-binding affinityP53K370me1SMYD2H1299(NSCLC cell), U2OS(osteosarcoma cell),\
BJ-DNp53(fibroblast cell)Inhibition^[@CR66]^HIF1αK32me1SET7RCC4(renal carcinoma cell)Inhibition^[@CR70]^HIF2αK29me1SET7RCC4(renal carcinoma cell)Inhibition^[@CR70]^P53K382me1SET8U2OS(osteosarcoma cell), H1299(NSCLC cell)Inhibition^[@CR67]^STAT3\
K140me2SET7DLD1(colon cancer cell)Inhibition^[@CR57]^RelAK37me1SET7293TActivation^[@CR73]^RelAK218me1,\
K221me2NSD1293C6, HT29(colon cancer cell)Activation^[@CR74]^ARK632me\*SET7Prostate cancer cellActivation^[@CR72]^YY1K173me1,\
K411me1SET7HeLa(cervical carcinoma)Activation^[@CR95]^YY2 K247me1SET7HeLa(cervical carcinoma)Activation^[@CR96]^Protein--protein bindingRelAK310me1SETD6293T, U2OS(osteosarcoma cell),\
THP1(mononuclear macrophage)Inhibition^[@CR82]^RBK860me1SMYD2293T, U2OS(osteosarcoma cell),\
NIH3T3(mouse embryonal fibroblast cell)Activation^[@CR76]^RBK873me1SET7U2OS(osteosarcoma cell), SAOS2(osteosarcoma cell),\
C2C12(myoblast), CC42 (fibroblast cell)Activation^[@CR77]^P53K382me2UnknownU2OS(osteosarcoma cell)Activation^[@CR75]^Crosstalk with other PTMsGATA4\
K299me1EZH2HL1(mouse cardio myocytes)Inhibition^[@CR97]^RBK810me1SET7U2OS(Osteosarcoma cell)Inhibition^[@CR81]^ERαK266me1SMYD2Breast cancerInhibition^[@CR79]^STAT3K180me\*EZH2GlioblastomaActivation^[@CR80]^Asterisks indicate that the methylation status is unknown^a^Methylation substrate, lysine site, and methylation degree^b^Lysine methyl transferases and synonyms: SET7 (KMT7, SET7/9, SET9, SETD7); EZH2 (KMT6A/KMT6); SET8 (PR-Set7, KMT5A, SETD8); NSD1 (KMT3B); SMYD2 (KMT3C)

Protein stability {#Sec9}
=================

Similar to phosphorylation-dependent ubiquitination^[@CR58],[@CR59]^, one study demonstrated that orphan nuclear receptor (RORα) protein stability can be dynamically regulated with methylation-dependent ubiquitination, which is carried out by damage-specific DNA-binding protein 1 (DDB1)/cullin4 (CUL4) E3 ubiquitin ligase complex and a DDB1-CUL4-associated factor 1 (DCAF1) adapter^[@CR60]^. Methyltransferase EZH2 has been found to methylate RORα at K38. Therefore, monomethylated RORα can be specifically recognized by DCAF1, comprising the putative chromo domain, inducing ubiquitination-dependent degradation through the DCAF1/DDB1/CUL4 axis. Of note, RORα has been proven to be a cancer suppressor^[@CR61]^. Research has demonstrated an oncogenic role of EZH2 through the facilitation of RORα methylation-dependent degradation, resulting in tumor development and progression^[@CR60]^.

In addition, previous studies have found that methyltransferase SET7 can methylate DNA-bound RelA (subunit of NF-κB) at lysine residues 314 and 315 in vivo in response to tumor necrosis factor-α (TNFα) stimulation^[@CR62]^, and the methylation is critical for the degradation of DNA-bound NF-kB and repress NF-kB target genes transcriptional activity.

Subcellular localization {#Sec10}
========================

Nucleocytoplasmic transport is a necessary step for transcription factor activity. Transcription factors modified by phosphorylation can acquire the ability to enter the nucleus^[@CR63]^. Similarly, lysine methylation can also change nuclear localization and regulate transcriptional activity.

For example, previous research has demonstrated that SET7 specifically methylated p53 at lysine 372, and methylated p53-K372 localized to the nucleus^[@CR64]^. On the other hand, p53 was shown to be equally distributed between the nuclear and cytosolic fractions. Notably, Chuikov and colleagues showed that p53 stabilization was apparent only in the fraction with chromatin-associated nuclear p53. Given that overexpression of wild-type SET7 resulted in hyper-stabilization and activation of nuclear p53; it could be expected that cell-cycle arrest and apoptosis would result^[@CR64]^.

Another research study found that the estrogen receptor (ER) could be directly methylated at lysine 302 by SET7. Remarkably, it was found that SET7-mediated methylation enhanced estradiol-induced nuclear accumulation and stability of ER, both of which were necessary for the efficient recruitment of ER to target genes and for subsequent transactivation in breast cancer cells^[@CR65]^.

DNA-binding affinity {#Sec11}
====================

Lysine methylation changes the binding ability of transcription factors to DNA and regulates their transcriptional activities. The regulatory outcome is related to protein substrate, modification site, and cell context.

Inhibition of DNA binding {#Sec12}
-------------------------

Dimethylation at K140 of signal transducer and activator of transcription 3 (STAT3) by SET7 has been demonstrated to be a negative regulatory event because blockade of this K140 dimethylation greatly increases activated steady-state STAT3 levels and subsequent binding to the promoter of STAT3 target genes^[@CR57]^.

It has been reported that the methyltransferase SMYD2 could methylate p53 at K370 in cancer cells^[@CR66]^. The published study by Huang et al. suggests that K370-methylation of p53 reduces DNA-binding efficiency, and SMYD2-mediated methylation at K370 shifts the equilibrium towards dissociation of p53 from DNA^[@CR66]^. On the other hand, SET7-mediated methylation of p53 at K372 enhances the association of p53 with promoters by blocking SMYD2-mediated methylation of K370, which promotes activation of the target genes^[@CR66]^. Additionally, another study found that p53 K382me1(lysine 382 monomethylation) generation by the methyltransferase SET8 negatively correlates with DNA damage, and SET8 co-expression reduces the occupancy of p53 at the promoters of the target genes *p21* and *PUMA*^[@CR67]^.

Hypoxia-inducible factor (HIF)-1 and HIF-2 are the main regulators of cellular responses to hypoxia^[@CR68],[@CR69]^. It has been demonstrated that SET7 methylation of HIF-1 at lysine 32 and HIF-2 at lysine 29 inhibits HIF-1/2 target gene expression by diminishing the occupancy of HIF-1/2 on hypoxia response elements of HIF target gene promoters^[@CR70]^. These data suggest that SET7-mediated lysine methylation negatively regulates HIF-1/2 transcriptional activity^[@CR70]^.

Promotion of DNA binding {#Sec13}
------------------------

Lysine methylation of transcription factors can also enhance DNA-binding affinity. For example, the androgen receptor is a member of the nuclear hormone receptor family of transcription factors that plays a critical role in regulating expression of genes involved in prostate cancer^[@CR71]^. Methylation of the androgen receptor at lysine 632 by SET7 is necessary for enhancing its transcriptional activity by recruitment to androgen receptor target genes and facilitating inter-domain communication between the N- and C-termini^[@CR72]^.

NF-κB is a key activator of inflammatory and immune responses with important pathological roles in cancer. SET7 has been found to specifically methylate RelA at lysine 37 with both TNFα and interleukin-1β (IL-1β) treatment^[@CR73]^. Methylated RelA is restricted to the nucleus and this modification increases its promoter binding affinity. These data suggest that methylation by SET7 enhances the affinity of RelA for DNA, which is a critical event for induction of NF-κB-dependent genes in response to TNFα stimulation. Methylation of K218 and K221 of RelA by the methyltransferase NSD1 plays a positive role in cell proliferation, colony formation, and gene expression in human cancer cells^[@CR74]^. However, interfering with the expression of NSD1 decreases both NF-κB activity and its ability to bind to DNA in the context of IL-1β treatment.

Protein--protein interactions {#Sec14}
=============================

Methylated lysine can be read by specific proteins and linked to specific biological effects on transcriptional activity. For example, dimethylated p53 at lysine 382 is recognized by p53-binding protein 1 (53BP1), which acts as an effector protein^[@CR75]^. This methylation event can promote the function of p53 in the context of DNA damage.

It has been demonstrated that RB can be methylated at lysine 860 by SMYD2^[@CR76]^. Furthermore, methylation of RB at K860 provides a direct binding site for the methyl-binding domain of the transcriptional repressor L3MBTL1, which helps to activate the RB function in cancer cells^[@CR27]^.

In addition, Munro et al. demonstrated that SET7 can methylate lysine 873 of RB both in vitro and in vivo, and methylated RB interacts with heterochromatin protein 1 (HP1)^[@CR77]^. Furthermore, increases in the levels of bound RB and HP1 on E2F target genes, as measured by chromatin immunoprecipitation, have been observed in conditions of growth arrest. Together, these results reveal that RB and HP1 interact in a SET7-dependent manner, and HP1 contributes to the transcriptional activity of RB^[@CR77]^.

Crosstalk with other post-translational modifications {#Sec15}
=====================================================

Like ubiquitin and phosphorylation^[@CR78]^, transcription factor lysine methylation is not limited to a single event. Many studies have found that lysine methylation can achieve distinct biological outcomes indirectly by acting in combination with other types of PMTs that occur at near or distant site^[@CR49]^.

Methylation--acetylation crosstalk {#Sec16}
----------------------------------

It is known that under estrogen-depleted conditions, SMYD2 attenuates chromatin recruitment of ERα to prevent ERα target gene transcriptional activation. Zhang et al. have shown that upon estrogen stimulation, K266 methylation of ERα is diminished^[@CR79]^. This allows acetyltransferase p300 response element-binding protein to acetylate ERα at K266, thereby promoting ERα transactivation activity. Furthermore, the knockdown of the demethylase LSD1 leads to increased methylation of ERα at K266 and decreased K266/268 acetylation, suggesting that ERα methylation at K266 is dynamically regulated by SMYD2 and LSD1. Taken together, these findings point to a model in which SMYD2 represses ERα target gene expression partly through the inhibition of ERα acetylation at K266/268^[@CR79]^.

Methylation--phosphorylation crosstalk {#Sec17}
--------------------------------------

It has been illustrated that EZH2 methylates STAT3 at lysine 180, leading to enhanced STAT3 activity by increasing tyrosine phosphorylation of STAT3^[@CR80]^. This EZH2--STAT3 interaction preferentially occurs in glioblastoma stem-like cells (GSCs) relative to non-stem tumor cells, and it requires a specific phosphorylation of EZH2^[@CR80]^.

A study by Carr et al. showed that methylation of RB at K810 by SET7 impedes binding of cyclin-dependent kinases, preventing subsequent phosphorylation of the associated serine residue^[@CR81]^. This results in retention of RB in the hyperphosphorylated growth suppressing state. In the context of SET7 depletion, RB phosphorylation was not apparent and a reduced expression of E2F target genes, including *DHFR*, *Cdc2,* and *Cdc6*, was seen. Together, the study confirms that SET7 antagonizes cyclin-dependent kinase-dependent cell-cycle progression^[@CR81]^.

Transcription factor and histone methylation modification crosstalk {#Sec18}
-------------------------------------------------------------------

Nuclear RelA monomethylation at K310 by the methyltransferase SETD6 attenuates NF-κB signaling by docking methyltransferase GLP (via its ankyrin repeats) to target genes^[@CR82]^. This generates a silent chromatin state (H3K9me3), effectively rendering chromatin-bound RelA inert. Therefore, methylation mediated by SETD6 can inhibit RelA target gene expression in an indirect way.

Biological effects of transcription factor lysine methylation in cancer {#Sec19}
=======================================================================

Lysine methylation is a dynamic process, a small number of transcription factors have been proven to be demethylated by specific KDMs^[@CR83]^ (Table [2](#Tab2){ref-type="table"}). Herein, we elucidate the comprehensive and dynamic transcription factor methylation processes from the literature and illustrate this summary in models depicted in Fig. [3](#Fig3){ref-type="fig"}. Methylation modification at specific sites of transcription factors and the effects on target gene expression and cell biology are shown.Table 2The known demethylation processes of transcription factorsSubstrateEnzymeTumor typeTranscription activityReferencesDemethylationP53K370me2LSD1293T, MCF7 (breast cancer cell),\
U2OS (Osteosarcoma cell)Inhibition^[@CR98]^P53K372me1KDM3ABreast cancerInhibition^[@CR84]^RelAK218me1, K221me2FBXL11293C6, HT29 (colon cancer cell)Inhibition^[@CR74]^ERαK266me1LSD1Breast cancerActivation^[@CR79]^YY2K247me1LSD1HeLa (cervical carcinoma)Inhibition^[@CR96]^Fig. 3The model of transcription factors in the context of lysine methylation in tumorigenesis.A summary from the current literature of the comprehensive and dynamic methylation processes of transcription factors is depicted in the following models, including of p53 **a**, RB **b**, RelA **c**, STAT3 **d**, ERα **e**, RORα **f**, and AR **g**. Post-translational modifications at specific sites of activate (in blue) and inactivate (in red) transcription factors, thereby affecting regulation of target gene expression specific for cellular biological processes associated with cancer

It is noteworthy that several transcription factors that control proliferation, apoptosis, stem cell properties, or drug resistance can be catalyzed by KMTs and KDMs. Unbalanced regulation of these transcription factors plays an important role in the tumor microenvironment, subsequently resulting in cancer initiation and development^[@CR36]^.

Proliferation {#Sec20}
=============

Recent research has revealed an NF-κB regulatory pathway that is driven by reversible methylation at K218 and K221 of the RelA subunit, carried out by the lysine methyltransferase NSD1 and the lysine demethylase FBXL11^[@CR74]^. Overexpression of FBXL11 inhibits NF-κB activity, but elevated NSD1 levels can activate NF-κB and reverse the inhibitory effect of FBXL11. The authors also showed that overexpression of FBXL11 slowed the growth of HT29 cancer cells, whereas shRNA-mediated knockdown of FBXL11 had the opposite effect, both of these phenotypes were K218/K221 methylation dependent^[@CR74]^.

Apoptosis {#Sec21}
=========

Chuikov et al. showed that SET9 can specifically methylate p53 at K372^[@CR64]^. Methylation of p53 restricts it to the nucleus and increases its stability. Overexpression of the catalytically inactive SET9 was shown to abrogate DNA damage-induced apoptosis, suggesting that the methyltransferase activity of SET9 is critical for induction of p53-dependent apoptosis. This research highlights another possible mechanism for p53 inactivation in human cancers^[@CR64]^.

On the other hand, SMYD2-mediated methylation of p53 at K370 shifts the equilibrium towards dissociation of p53 from DNA and downregulates expression of *p21* and *MDM2*, thereby inhibiting cell apoptosis^[@CR66]^.

Chemotherapy sensitivity {#Sec22}
========================

A study by Ramadoss et al. demonstrated that KDM3A suppresses the proapoptotic functions of p53 by removing p53-K372me1^[@CR84]^. This specific methylation is crucial for the stability of chromatin-bound p53. Unexpectedly, the authors found that inhibition of KDM3A reactivated mutant p53 and induced the expression of proapoptotic genes, thereby restoring apoptotic sensitivity to chemotherapeutic drugs. Taken together, these data suggest that KDM3A might be a potential therapeutic target for human breast cancer treatment and prevention^[@CR84]^.

Stem cell properties {#Sec23}
====================

Research has shown that EZH2 can methylate STAT3 at K180 in GSCs, which leads to enhanced STAT3 activity by subsequent increases in tyrosine phosphorylation of STAT3^[@CR80]^. This increased STAT3 activity can contribute to GSC self-renewal and glioblastoma multiforme malignancy.

Discussion {#Sec24}
==========

Lysine methylation of transcription factors is emerging as an important and dynamic PTM to activate or repress target gene expression in response to extracellular signals. Like phosphorylation and acetylation, lysine methylation can directly alter distinct aspects of transcription factor function, including protein stability, cellular localization, DNA-binding affinity, protein--protein interactions, and crosstalk with other PTMs. The biomedical significance of lysine methylation of transcription factors in several human diseases has been explored in recent years. In this review, we summarize the current literature of transcription factor lysine methylation and its role in cancer. We outline the biological significance of this PTM, including effects on proliferation, apoptosis, stem cell properties, and drug resistance in cells, highlighting the importance of transcription factor lysine methylation in carcinogenesis.

Epigenetics provides promising new targets for anticancer therapy^[@CR85]^. DNA methylation and histone acetylation have been pharmacologically targeted, and several DNA methyltransferase and histone deacetylase inhibitors are FDA-approved for cancer treatment^[@CR86],[@CR87]^. Since methylation is involved in such fundamental cellular functions and is dysregulated in diseases^[@CR88]^, the investigation of its role in cancer has led to the identification of KMTs and KDMs as promising novel targets for cancer therapy^[@CR89]--[@CR91]^. Lysine methylation of transcription factors plays a prominent role in cancer, providing rationale for the development of KMTs and KDMs inhibitors.

Although additional research is required to further understand protein lysine methylation, investigation into inhibitors of methylation regulatory proteins as anticancer drugs is underway and has made considerable progress in recent years^[@CR92]--[@CR94]^. Encouragingly, experiments have demonstrated that targeting transcription factor methylation can provide novel therapeutic strategies to target gene mutations and drug resistance in cancer therapy^[@CR84]^. For example, the lysine-specific demethylase KDM3A has dual carcinogenic effects in breast cancer^[@CR84]^. By erasing methylation at lysine 9 of histone H3, KDM3A induces preinvasive gene expression. KDM3A can also promote chemotherapy resistance by erasing p53-K372me1. Significantly, depletion of KDM3A is capable of reactivating mutant p53 to induce proapoptotic gene expression. In conclusion, targeting transcription factor methylation can provide new treatment opportunities for overcoming gene mutation and chemotherapeutic resistance in tumors. With the further study of transcription factor lysine methylation, we believe greater clinical therapeutic potential will be explored in the future.

Edited by I. Amelio

**Publisher's note:** Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

These authors contributed equally: Dong Han, Mengxi Huang, Ting Wang.

This work was supported by the grants from the National Natural Science Foundation of China (NSFC nos. 81572457, 81702442, and 81872042), Natural Science Foundation of Jiangsu province, China (no. BK20170623) and Postdoctoral Science Foundation of Jiangsu province, China (no. 2018K090B).

H. D., H. M. X., and W. T. were the major contributors in writing and revising the manuscript. L. Z. P., C. Y. Y., and L. C. performed the literature search. L. Z. J. and C. X. Y. participated in the design of the review and helped to finalize the manuscript. All authors read and approved the final manuscript.

Conflict of interest {#FPar1}
====================

The authors declare that they have no conflict of interest.
